Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 20 for “"Lucentis"”.

  1. Monoclonal Antibody Separation: Lucentis from Genentech

    … design project focuses on the bioseparation of Lucentis (Genentech Inc.), a humanized anti-VEGF-A monoclonal antibody fragment used to treat macular degeneration. Vascular endothelial growth factor, VEGF, promotes blood vessel growth in the wet form of macular degeneration. These fragile blood …

    unr Repository record for Monoclonal Antibody Separation: Lucentis from Genentech (opens in a new tab)

  2. Optimization of Downstream Purification of Lucentis

    … and purification of the fragmented antibody, Lucentis, was explored and compared to several alternative cases that were hypothesized to optimize the purification process. The base case consisted of using a series of chromatography columns including anion exchange, cation exchange, and …

    unr Repository record for Optimization of Downstream Purification of Lucentis (opens in a new tab)

  3. Tangential Flow Filtration for the Purification of Lucentis

    … to design a process to manufacture and purify a "Lucentis®-like" (Lu-L) protein. This group has been working on the tangential flow filtration (TFF) portion of the project, which will be utilized multiple times throughout the separation and purification process. The primary purpose of tangential …

    unr Repository record for Tangential Flow Filtration for the Purification of Lucentis (opens in a new tab)

  4. Behandlung der neovaskulären altersabhängigen Makuladegeneration mit Ranibizumab (Lucentis) im klinischen Alltag

    Die gegenwärtige Behandlung der neovaskulären AMD mit 0,5 mg Ranibizumab besteht aus einer 3-monatigen Aufsättigungsphase und einer bedarfsabhängigen Erhaltungsphase. Die vorliegende nicht interventionelle Studie hatte zum Ziel, während des 12-monatigen Beobachtungszeitraums das Behandlungsschema …

    fu-berlin Repository record for Behandlung der neovaskulären altersabhängigen Makuladegeneration mit Ranibizumab (Lucentis) im klinischen Alltag (opens in a new tab)

  5. Optimization of Downstream Processing of a Monoclonal Antibody

    … Reno on the antibody separation processes for Lucentis. Lucentis is a humanized anti vascular endothelial growth factor (VEGF) monoclonal antibody fragment used to treat macular degeneration. VEGF promotes blood vessel growth in the wet form of macular degeneration which leads to bleeding …

    unr Repository record for Optimization of Downstream Processing of a Monoclonal Antibody (opens in a new tab)

  6. Genentech: Purification of Monoclonal Antibody

    Lucentis, a monoclonal antibody fragment produced in Escherichia coli, is used to treat wet age-related macular degeneration, one of the leading causes of legal blindness. The objective of this thesis is to analyze the process of antibody fragment separation and to purify a solution of "Lucentis …

    unr Repository record for Genentech: Purification of Monoclonal Antibody (opens in a new tab)

  7. Genentech Senior Design Project: Purification of a Ranibizumab-like Protein

    … monoclonal antibody similar to Ranibizumab, or "Lucentis", which is used in the treatment of wet age-related macular degeneration of the eyes, a leading cause of blindness. A focus on the chromatographical purification of Lucentis is provided, and both base and alternate cases for a complete …

    unr Repository record for Genentech Senior Design Project: Purification of a Ranibizumab-like Protein (opens in a new tab)

  8. Genentech: Cell Fermentation

    A challenge to grow E. coli and express a Lucentis-like protein of interest in the laboratories of the Department of Chemical and Materials Engineering at the University of Nevada, Reno is presented by Genentech. A potential model to achieve this goal is created involving a bioreactor hosted in the …

    unr Repository record for Genentech: Cell Fermentation (opens in a new tab)

  9. Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen

    … vorzubeugen gilt. Mittlerweile sind Lucentis® als Anti-VEGF-Inhibitor sowie Ozurdex® als Steroid-Implantat (Dexamethason) zur Behandlung des Makulaödems bei venösen Gefäßverschlüssen zugelassen und stellen in der Therapie von RVV neben der konventionellen Laserbehandlung eine …

    lmu-germany Repository record for Vergleich von intravitrealem Dexamethason-Implantat mit intravitrealem Ranibizumab zur Behandlung des Makulaödems bei retinalen venösen Gefäßverschlüssen (opens in a new tab)

  10. Biosynthesis of polyhydroxyalkanoates and their medical applications

    … were encapsulated with three model proteins BSA, Lucentis® and RNase A to understand the effect of morphology, drug distribution on the in vitro release profiles. The microspheres produced were of an average size of 2μm. P(3HB) microspheres investigated for use as drug delivery vehicles in the …

    westminster Repository record for Biosynthesis of polyhydroxyalkanoates and their medical applications (opens in a new tab) Download PDF for Biosynthesis of polyhydroxyalkanoates and their medical applications (opens in a new tab)

  11. Reakcja ekosystemu wodnego na zabiegi rekultywacyjne na przykładzie Jeziora Swarzędzkiego

    … przed degradacją zbiornika – Potametum lucentis. Zmiany te wynikały ze zwiększenia zasięgu promieniowania słonecznego oraz zmniejszenia stężeń nutrientów. Stwierdzono też skrócenie okresu beztlenowego w warstwie naddennej oraz obniżenie koncentracji azotu oraz fosforanów przy dnie …

    amu-pl Repository record for Reakcja ekosystemu wodnego na zabiegi rekultywacyjne na przykładzie Jeziora Swarzędzkiego (opens in a new tab)

  12. Erfahrungen mit intravitrealem Bevacizumab (Avastin®) bei exsudativer, altersabhängiger Makuladegeneration

    … Makuladegeneration. Mit der Zulassung von Lucentis Ende Januar 2007 und regelmäßigen Injektionen kam es zu einer Änderung der Therapieoptionen der CNV bei exsudativer AMD. Die Einjahres- und Zweijahresergebnisse der CATT- Studien zeigten, dass sich Lucentis und Avastin nicht signifikant …

    qucosa-diss

  13. Comparison of Tissue Contractile Responses of Rat Models of Pulmonary Artery Hypertension and Type I/II Diabetes

    … that will purify a monoclonal antibody (Lucentis) grown and extracted from e. coli for the purpose of treating the "wet" form of macular degeneration. The following units will be explored, in this determined order: homogenizer, centrifuge, column chromatography, tangential flow …

    unr Repository record for Comparison of Tissue Contractile Responses of Rat Models of Pulmonary Artery Hypertension and Type I/II Diabetes (opens in a new tab)

  14. Development of polymeric nanoparticulate formulation encapsulating protein molecules following hydrophobic ion pairing complexation

    … parameters with IgG-Fab fragment, ranibizumab (Lucentis®), an anti-VEGF antibody fragment used for the treatment of age-related macular degeneration, loaded nanoparticulate formulation was also successfully developed. Developed nanoparticles formulations were characterized with respect to …

    umkc Repository record for Development of polymeric nanoparticulate formulation encapsulating protein molecules following hydrophobic ion pairing complexation (opens in a new tab)

  15. Die Rolle von löslichen Faktoren bei der Hemmung der T-Zell-Aktivierung durch humane retinale Pigmentepithelzellen

    … Bevacizumab (Avastin™, Roche) und Ranibizumab (Lucentis™, Novartis) auf die Hemmung der T-Zell-Proliferation durch humane RPE-Zellen geprüft. <br>Methode: Humane T-Lymphozyten von verschiedenen Spendern wurden in Ko-Kulturen mit den humanen RPE-Zelllinien ARPE-19 und M154 mit anti-CD3- und …

    freiburg-diss Repository record for Die Rolle von löslichen Faktoren bei der Hemmung der T-Zell-Aktivierung durch humane retinale Pigmentepithelzellen (opens in a new tab)

  16. Ο ρόλος των αντινεοαγγειακών παραγόντων στο διαβητικό οίδημα της ωχράς

    … the advent of the anti-VEGF therapy ranibizumab (Lucentis, Genentech) for diabetic macular edema (DME) The most significant effect that the RISE and RIDE data have had is that patients with center-involving DME have a good chance of substantially improving their vision vs what was possible with …

    greece Repository record for Ο ρόλος των αντινεοαγγειακών παραγόντων στο διαβητικό οίδημα της ωχράς (opens in a new tab)

  17. Διερεύνηση της γενετικής βάσης στην αντιμετώπιση της ηλικιακής εκφύλισης της ωχράς κηλίδας

    … injections with a dose of 0.5 mg ranibizumab (Lucentis®). Treatment response was evaluated by comparing visual acuity and optical coherence tomography (OCT) between baseline and the end of the treatment. Patients were classified as responders and non-responders based on OCT and visual acuity …

    greece Repository record for Διερεύνηση της γενετικής βάσης στην αντιμετώπιση της ηλικιακής εκφύλισης της ωχράς κηλίδας (opens in a new tab)